Company Kuros Biosciences AG Swiss Exchange
Equities
CH0325814116
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.345 CHF | +164.38% | +0.42% | +3.91% |
24/04 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
17/04 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Business Summary
Sales per Business
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medical Devices
100.0
%
| 13 | 73.8 % | 34 | 100.0 % | +153.03% |
Sales per region
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
97.8
%
| 17 | 96.6 % | 33 | 97.8 % | +88.93% |
European Union
1.7
%
| 0 | 2.4 % | 1 | 1.7 % | +35.20% |
Other
0.4
%
| 0 | 1.0 % | 0 | 0.4 % | -17.82% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 17/23/17 |
Chief Tech/Sci/R&D Officer | - | 01/17/01 | |
Sjoerd Musters
COO | Chief Operating Officer | - | 01/22/01 |
Luuk van Dijk
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Katherine Sage
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
John Griffin
PRN | Corporate Officer/Principal | - | 12/23/12 |
Marcel Borger
LAW | General Counsel | - | 01/20/01 |
Philippe Saudan
PRN | Corporate Officer/Principal | 57 | 10/16/10 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 14/18/14 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
Chairman | 67 | 23/17/23 | |
Oliver Walker
BRD | Director/Board Member | 55 | 14/18/14 |
Leanna Caron
BRD | Director/Board Member | 56 | 16/16/16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 36,866,049 | 23,857,779 ( 64.71 %) | 17,244 ( 0.0468 %) | 64.71 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
KUROS BIOSCIENCES AG 3.15% | 1,160,106 | 3.15% | 7,805,309 $ |
Company contact information
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-2.63% | 102B | |
+1.62% | 96.29B | |
+2.13% | 22.18B | |
-16.67% | 21.2B | |
-8.14% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- KURN Stock
- Stock
- Company Kuros Biosciences AG